WILLIAM J. LINK PHD - 12 Aug 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
12 Aug 2024
Net transactions value
-$912,961
Form type
4
Filing time
14 Aug 2024, 16:34:26 UTC
Previous filing
25 Jun 2024
Next filing
28 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Other $0 -74,892 -68% $0.000000 35,000 12 Aug 2024 By Flying L Partners XI, LLC F1, F2
transaction TARS Common Stock Other $0 +10,446 $0.000000 10,446 12 Aug 2024 By Link Family Enterprise, LP F1, F3
transaction TARS Common Stock Other $0 +27,116 +19% $0.000000 167,098 12 Aug 2024 Direct F1
transaction TARS Common Stock Sale $779,754 -29,979 -86% $26.01 5,021 12 Aug 2024 By Flying L Partners XI, LLC F2, F4
transaction TARS Common Stock Sale $133,207 -5,021 -100% $26.53 0 12 Aug 2024 By Flying L Partners XI, LLC F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Partners XI, LLC to its partners.
F2 The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
F3 The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F4 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.42 to $26.41. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.42 to $26.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.